Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Psychometric analysis of the Korean version of the high-dose chemotherapy specific quality of life questionnaire module from the European Organization for Research and Treatment of Cancer (EORTC QLQ-HDC29)

Authors
Kim, Kyung ImKim, Jae HyunJi, Eun HeeJang, Jun HoKim, Jin SeokKwon, Ji-HyunKim, InhoPark, SeonyangVelikova, GalinaYoon, Sung-SooOh, Jung Mi
Issue Date
4월-2016
Publisher
SPRINGER
Keywords
Hematopoietic stem cell transplantation; High-dose chemotherapy; QLQ-HDC29; Quality of life; Validation
Citation
QUALITY OF LIFE RESEARCH, v.25, no.4, pp.881 - 890
Indexed
SCIE
SSCI
SCOPUS
Journal Title
QUALITY OF LIFE RESEARCH
Volume
25
Number
4
Start Page
881
End Page
890
URI
https://scholar.korea.ac.kr/handle/2021.sw.korea/88982
DOI
10.1007/s11136-015-1121-5
ISSN
0962-9343
Abstract
We evaluated the psychometric properties of the Korean version of the European Organization for Research and Treatment of Cancer high-dose chemotherapy specific quality of life questionnaire module (EORTC QLQ-HDC29) when implemented with Korean patients by conducting a multicenter, longitudinal study in three Korean hospitals. A total of 226 patients who scheduled to receive the HDC followed by hematopoietic stem cell transplantation (HSCT) were enrolled. The patients were asked to complete three questionnaires [the EORTC Core Questionnaire (QLQ-C30), QLQ-HDC29, and the Functional Assessment of Cancer Therapy-Bone Marrow Transplantation] at four points in time: before HSCT and 100, 180, and 365 days after HSCT. Standard validity and reliability analyses were performed. Internal consistency of the QLQ-HDC29 was generally acceptable, as tested by Cronbach's alpha, except for the scales body image and the inpatient issues. Cronbach's alpha values for the Korean version of the QLQ-HDC29 were almost in accordance with results of the original version, except for the scales body image (lower to the original QLQ-HDC29, alpha = 0.73) and impact on family (higher to the original QLQ-HDC29, alpha = 0.52). Known-group comparison analyses showed significantly higher symptom burdens in patients with poor performance status or graft versus host disease (similar to the original QLQ-HDC29). The QLQ-HDC29 indicated good convergent and discriminant validity and showed responsiveness to changes in line with a clinical course over time after HSCT. The QLQ-HDC29 is generally reliable and adequate to assess QoL in Korean patients undergoing HDC followed by HSCT.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Pharmacy > Department of Pharmaceutical Science > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Kim, Kyung Im photo

Kim, Kyung Im
약학대학 (약학과)
Read more

Altmetrics

Total Views & Downloads

BROWSE